Review




Structured Review

GenomeDx Inc genome-wide microarray gene expression data
Genome Wide Microarray Gene Expression Data, supplied by GenomeDx Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+data+from+microarray+experiments/genome+wide+microarray+gene+expression+data/pmc08602290-96-21-33
Average 90 stars, based on 1 article reviews
genome-wide microarray gene expression data - by Bioz Stars, 2026-09
90/100 stars

Images

Related Articles

Genome Wide:

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada) .

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer.
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada)37.

Article Title: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Article Snippet: We used the SCaPT model to predict the molecular subclass from a retrospective cohort that included 1,626 patient samples and a prospective cohort that included 6,532 samples using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada), and we explored the clinicopathologic and prognostic associations of key molecular subclasses of prostate cancer.

Microarray:

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada) .

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer.
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada)37.

Article Title: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Article Snippet: We used the SCaPT model to predict the molecular subclass from a retrospective cohort that included 1,626 patient samples and a prospective cohort that included 6,532 samples using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada), and we explored the clinicopathologic and prognostic associations of key molecular subclasses of prostate cancer.

Gene Expression:

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada) .

Article Title: G3BP1 inhibits Cul3 SPOP to amplify AR signaling and promote prostate cancer.
Article Snippet: We evaluated the probability of metastasis-free survival of primary 1626 PCa patients stratified based on low or high G3BP1 group using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada)37.

Article Title: Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Article Snippet: We used the SCaPT model to predict the molecular subclass from a retrospective cohort that included 1,626 patient samples and a prospective cohort that included 6,532 samples using genome-wide microarray gene expression data from a clinically available prognostic assay (Decipher; GenomeDx Biosciences, Vancouver, BC, Canada), and we explored the clinicopathologic and prognostic associations of key molecular subclasses of prostate cancer.



Similar Products

90
Biopharm GmbH gene expression data from microarray experiments
Gene Expression Data From Microarray Experiments, supplied by Biopharm GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gene+expression+data+from+microarray+experiments/gene+expression+data+from+microarray+experiments/pm23000192-394-24-27
Average 90 stars, based on 1 article reviews
gene expression data from microarray experiments - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results